BNB Plus (BNBX) investor relations material

Executive summary

• Shifted focus to a digital asset treasury strategy centered on BNB, the Binance blockchain's native cryptocurrency, while continuing to commercialize nucleic acid production solutions through its LineaRx subsidiary.

• Completed a major restructuring, reducing workforce by over 60% and winding down legacy business lines to prioritize the BNB strategy.

• Recent delisting from Nasdaq due to minimum bid price non-compliance; now trading on OTCQB Venture Market.

• Entered into a settlement with Cypress, terminating all advisory and consulting agreements and transitioning BNB treasury management fully in-house.

Financial highlights

• Product revenues for the quarter ended June 30, 2026 rose 200% year-over-year to $585,551, driven by large-scale DNA manufacturing sales.

• Service revenues declined 82% year-over-year to $19,755 due to reduced activity in legacy segments.

• Gross profit for the quarter increased to $447,122 (74% margin), up from $5,130 (2% margin) in the prior year, reflecting higher product sales and lower overhead.

• Net loss for the quarter was $4.68 million, compared to $3.95 million in the prior year.

• For the nine months ended June 30, 2026, product revenues grew 73% to $2.15 million, while service revenues fell 93% to $46,264.

• Gross profit for the nine months increased 58% to $1.59 million (72% margin).

• Net loss for the nine months was $29.95 million, up from $9.99 million in the prior year, driven by higher consulting and non-cash expenses related to the digital asset strategy.

Outlook and guidance

• Management believes current cash, equivalents, and liquid crypto assets are sufficient to fund operations for at least the next twelve months.

• Plans to continue expanding BNB reserves and pursue yield opportunities in Binance and DeFi ecosystems.

• Ongoing strategic review and capital raising efforts, including warrant exercises and at-the-market offerings.